ReConception Solutions aims to bridge the longstanding gaps in accessibility, affordability, outcomes, and available treatment options for patients facing fertility challenges. We strive to empower OB-GYNs with our cutting-edge, in-office medical innovations, enhancing their ability to provide exceptional care to more people.
OUR MISSION & VISION
Become the global leader in revolutionizing frontline fertility treatments.
mission
vision
INFERTILITY MARKET
The fertility space is plagued by inaccessibility, high costs, inconsistent outcomes, and trauma, amplifying the need for novel treatments to aid in conception, thus encouraging more people to pursue front-line fertility options.
13.4 M
500
$60k
48%
$5.71 Billion
people struggling with infertility in the u.s.
REI CLinics in the u.s.
>50% of patients travel >60 miles to an rei clinic
Median cost per live birth with ivf
Nearly 50% of people do not seek treatment after evaluation
U.S. market size
ReConception Solutions has a wide range of issued patents across three unique fertility devices with global IP protection.
INTELLECTUAL PROPERTY
OUR PLATFORM
A device platform that closes the gap in fertility success through newly conceived front-line solutions, improving outcomes and reducing procedural trauma and discomfort
Intrauterine Insemination (IUI) Delivery System
Precise visual evaluation & abrasion system
At-home semen collection & filtration system
Disclaimer: The medical devices discussed on this website have not been approved or cleared by the U.S. Food and Drug Administration (FDA). These products are not intended for use in diagnosing, treating, curing, or preventing any disease. Please consult a licensed healthcare professional before using any medical device.
Click here for a demo of our iui delivery system device
OUR TEAM
William is a seasoned P&L operating executive and entrepreneur with over 35 years of leadership experience in medical device and biotechnology start-ups. He has a proven track record of commercially orchestrating and launching over a dozen transformative technologies globally and building high-performing, patient-focused teams. William has successfully raised more than $120 million in funding and has led key functions such as R&D, finance, manufacturing, business development, and commercial operations, with a focus on driving operational excellence in high-growth, scalable businesses.
Benjamin is a dynamic leader with a proven track record in corporate strategy, operational excellence, and transformational programs. With extensive experience across Fortune 500 companies, private equity, and startups, he has successfully driven impactful change and sustainable growth. As a former EY consultant, Benjamin has led multi-million-dollar transactions, implemented large-scale efficiency improvements, and consistently delivered measurable results. His expertise lies in designing and executing innovative strategies that enhance profitability, streamline operations, and build value.
Experienced advising in process improvement, business strategy, and program optimization. Experience spanning multiple industries within healthcare, including Payers, Providers, Biotechnology, Health Finance, Life Sciences, and Health Technology.
Don has extensive pharmaceutical experience in sales, marketing, business development, R&D and manufacturing in several pharmaceutical companies including BMS, Novartis, Daiichi, Shire, Elan and Zebec. His experience includes the divestiture and acquisition of several companies and numerous products. He has also been involved in the identification, evaluation and development of six startup companies including a women’s health company and has raised over $100 million.
Experienced early-stage healthtech investing, commercialization, and market access, insurtech; executive leadership and organizational management. Previously: EIR, Postdoc researcher in biomedical data science evaluating efficacy and value realization of predictive analytics.
Dr Smith is a Biotech/Pharmaceutical Executive, Board Director and Clinical/Scientific Advisor. Her breadth of experience covers 100+ clinical trials and 20+ regulatory approvals in multiple jurisdictions leading to product launches across diverse therapeutic areas including oncology, rare disease, cardiology, dermatology, neuroscience, and anti-infectives. In addition to growth and creation of R&D pipelines, Dr Smith’s successful record of business development includes acquisitions, divestitures, and partnership deals. Dr Smith has held various clinical and business roles over the past 20 years including President, CEO, Global Head R&D, and Chief Medical Officer. She has built companies from the ground up and is a strong advocate for women in science and diversity in the Boardroom.
